New obesity drug tested in chinese adults for first time
NCT ID NCT06352892
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a single injection of a new drug called AMG 133 (Maridebart Cafraglutide) in 20 overweight or obese Chinese adults. The main goal was to see how the drug moves through the body and to check for any safety issues. This is a first step to see if the drug might be a future treatment for obesity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Maridebart Cafraglutide (AMG 133)
- What this could lead to
- If successful, this could support further development of AMG 133 as a weight management option for people with obesity.
- What could go wrong
- This is a very early Phase 1 study with only 20 participants. It is designed to check safety and drug levels, not to prove weight loss. Many early-stage drugs do not advance to later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Queen Mary Hospital
Hong Kong, 000, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?